PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the Subcommittee on Health.
Congressional Research Service
Version 00 · Introduced in House · Oct 17, 2005
Pandemic Preparedness and Response Act - Amends the Public Health Service Act to require the President to appoint a National Director of Pandemic Preparedness and Response to strengthen, expand, and coordinate domestic pandemic influenza preparedness activities.
Establishes the Pandemic Influenza Preparedness Policy Coordinating Committee to develop an Interagency Preparedness Plan.
Requires states to have an approved state preparedness plan as a condition of receiving certain funds related to bioterrorism.
Showing the opening paragraphs of the official summary.
Provides for the integration and coordination of public and private influenza surveillance activities.
Directs the Secretary of Health and Human Services to: (1) procure antivirals, developed vaccines, and essential medications for the Strategic National Stockpile; (2) develop a national system for tracking and distributing antiviral medications and vaccines; and (3) assist other counties in preparation for, and response to, pandemic influenza.
Provides for the expansion and intensification of influenza research.
Directs the Secretary to contract with the Institute of Medicine to study topics related to the pandemic influenza.
Establishes the National Pandemic Influenza Economics Advisory Committee.
Requires the Secretary of Agriculture to expand and intensify efforts to prevent pandemic influenza.
Requires the Secretary of Health and Human Services to: (1) enter into contracts with manufacturers to produce additional necessary doses of the influenza vaccine; and (2) develop a national plan for responding to potential influenza vaccine shortages.
Sets forth prohibitions against charging excessive prices during a public health emergency for, reporting false pricing information to the Secretary about, or employing a manipulative or deceptive device or contrivance in connection with the purchase or sale of, drugs, devices, or biologics for the prevention or treatment of influenza at wholesale.
People & committees
Rep. Lowey, Nita M. [D-NY-18] · D–NY
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We currently store references to these documents.
Source last updated: Aug 15, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.4062 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.4062 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.4062 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.4062 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.